

Pharmacy Name: Vital Care infusion services of Jacksonville Phone: 904-900-7077 Address: 8110 Cypress Plaza Dr, Ste 301

City/State/Zip: Jacksonville, FL 32256

Fax: 904-900-7078 Email: info@vitalcarejax.com

Gastroenterology Referral Form						
			f Insurance Cards (Front & Back)**			
Last Name: First Name:		DOB:	Practice:			
Address:				Address:		
City:	State	: Zip:	Sex: OM OF	City: Sta	ate: Zip:	
Phone: SSN#				Prescriber Name:		
Insurance Information Prescriber NPI:						
Insurance Plan: Insurance Plan:				Nurse/Key Contact:		
Policy # Policy #			Phone:			
Plan I.D. #			Fax: Email:			
Diagnosis & Clinical Information						
	Please At	tach Clinical/Progress Notes, La	abs, Test, Supporting Primary Diag	nosis		
Crohn's Disease Diagnosis code: Ulcerative Colitis Diagnosis code: Other:			TB/PPD Test: Positive Negative Date:			
Currently received and/or prior filed therapies: Length of treatment: Reason for discontinuation:			NKDA Height: Weight: Site of Care: Home AIC Other:			
					·	
		Prescrip	tion Information			
Medication	Dose/Strength	Prescript	tion Information Directions		Refills	
Entyvio	Dose/Strength	INITIAL: Infuse 300mg	Directions g IV at week 0, 2, 6, then every		Refills	
	_	INITIAL: Infuse 300mg	Directions g IV at week 0, 2, 6, then every e 300mg IV every w	eeks		
Entyvio (vedolizumab) Inflectra (infliximab) Remicade	_	INITIAL: Infuse 300mg MAINTENANCE: Infus INITIAL: Infuse MAINTENANCE: Infus Other	Directions g IV at week 0, 2, 6, then every e 300mg IV every w mg/kg IV at week 0, 2, 6, e mg/kg IV every	eeks then every 8 weeks thereat weeks	fter	
Entyvio (vedolizumab) Inflectra (infliximab)	300mg vial	INITIAL: Infuse 300mg MAINTENANCE: Infuse INITIAL: Infuse MAINTENANCE: Infuse Other Pharmacist will round INITIAL: Weight based	Directions g IV at week 0, 2, 6, then every e 300mg IV every w mg/kg IV at week 0, 2, 6, e mg/kg IV every I to the nearest 100mg Gi dosing, infuse IV 60mg (2 vials) 5	eeks then every 8 weeks thereat weeks	ifter und)	
Entyvio (vedolizumab) Inflectra (infliximab) Remicade Renflexis	300mg vial	INITIAL: Infuse 300mg MAINTENANCE: Infuse INITIAL: Infuse MAINTENANCE: Infuse Other Pharmacist will round INITIAL: Weight based Infuse Stream 55kg or less: 2	Directions g IV at week 0, 2, 6, then every e 300mg IV every w mg/kg IV at week 0, 2, 6, e mg/kg IV every I to the nearest 100mg Gir dosing, infuse IV	eeks then every 8 weeks thereat weeks ve exact dose (do NOT rou 5kg to 85kg: 390mg (3 vial	ifter ind)	
Entyvio (vedolizumab) Inflectra (infliximab) Remicade Renflexis	300mg vial 100mg vial	INITIAL: Infuse 300mg MAINTENANCE: Infuse INITIAL: Infuse MAINTENANCE: Infuse Other Pharmacist will round INITIAL: Weight based J 55kg or less: 2 Greater than 8 MAINTENANCE: Inject INITIAL: Infuse 600mg	Directions g IV at week 0, 2, 6, then every e 300mg IV every w mg/kg IV at week 0, 2, 6, e mg/kg IV every I to the nearest 100mg Gir dosing, infuse IV 60mg (2 vials)	eeks then every 8 weeks thereat weeks e exact dose (do NOT rou bkg to 85kg: 390mg (3 vial dose, then every 8 weeks t	ind) Ils) thereafter	
Entyvio (vedolizumab) Inflectra (infliximab) Remicade Renflexis Stelara (ustekinumab) Skyrizi (risankizumab) Pre-medication * Infusion supp	300mg vial 100mg vial 130 mg / 26ml vial 90mg (2x 45mg vials)	INITIAL: Infuse 300mg MAINTENANCE: Infuse INITIAL: Infuse MAINTENANCE: Infuse Other Pharmacist will round INITIAL: Weight based J 55kg or less: 2 Greater than 8 MAINTENANCE: Inject INITIAL: Infuse 600mg	Directions g IV at week 0, 2, 6, then every e 300mg IV everyw mg/kg IV at week 0, 2, 6, e mg/kg IV every It to the nearest 100mg Gir dosing, infuse IV 60mg (2 vials)	then every 8 weeks thereat weeks weeks we exact dose (do NOT rou 5kg to 85kg: 390mg (3 vial dose, then every 8 weeks to	ifter und) thereafter reeks thereafter ol	

PRESCRIBER MUST MANUALLY SIGN - STAMP SIGNATURE, SIGNATURE BY OTHER PERSONNEL AND COMPUTER-GENERATED SIGNATURES WILL NOT BE ACCEPTED

The attached document(s) contain confidential information which may be considered to be Protected Health Information and therefore required to be maintained as private and secure under HIPAA. The documents may also contain information which is otherwise considered to be privileged under state and federal laws. This communication is for the intended recipient only. If you are not the intended recipient, or a person responsible for delivering this communication to the intended recipient, you can be probablised from viewing, copying and/or distributing the information contained herein Unlawful disclosure of the information attached may subject you to monetary penalties and sanctions. If you have received this communication in error, you should notify the sender immediately and thereafter permanently destroy all copies of this document in its entirety.